Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

Verdict

Headline takes no side. We score CLDX +1.00 across three claims — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · CLDX

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 98% of ticker scores this week

What matters in this story